End-of-day quote
OTC Markets
18:00:00 2024-05-08 EDT
|
5-day change
|
1st Jan Change
|
0.0007
USD
|
0.00%
|
|
0.00%
|
+16.67%
|
Fiscal Period: December |
2021
|
---|
Capitalization
1 |
73.82
|
Enterprise Value (EV)
1 |
88.1
|
P/E ratio
|
-0.79
x
|
Yield
|
-
|
Capitalization / Revenue
|
49,642,171
x
|
EV / Revenue
|
59,246,379
x
|
EV / EBITDA
|
-2,843,602
x
|
EV / FCF
|
-8,699,064
x
|
FCF Yield
|
-0%
|
Price to Book
|
-52
x
|
Nbr of stocks (in thousands)
|
32,096
|
Reference price
2 |
2.300
|
Announcement Date
|
22-10-06
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
-
|
-
|
1.487
|
EBITDA
|
-
|
-
|
-10.5
|
-30.98
|
EBIT
1 |
-7.924
|
-3.002
|
-10.5
|
-31.24
|
Operating Margin
|
-
|
-
|
-
|
-2,100.68%
|
Earnings before Tax (EBT)
1 |
-6.132
|
-3.224
|
-12.09
|
-101.9
|
Net income
1 |
-6.132
|
-3.224
|
-12.09
|
-101.9
|
Net margin
|
-
|
-
|
-
|
-6,849.25%
|
EPS
2 |
-0.3586
|
-0.1644
|
-0.5610
|
-2.901
|
Free Cash Flow
|
-
|
1.605
|
-4.63
|
-10.13
|
FCF margin
|
-
|
-
|
-
|
-681.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-02-16
|
21-02-16
|
21-05-07
|
22-10-06
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
1.56
|
1.8
|
1.41
|
14.3
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1342
x
|
-0.461
x
|
Free Cash Flow
|
-
|
1.61
|
-4.63
|
-10.1
|
ROE (net income / shareholders' equity)
|
-
|
91.2%
|
308%
|
3,947%
|
ROA (Net income/ Total Assets)
|
-
|
-877%
|
-1,266%
|
-176%
|
Assets
1 |
-
|
0.3675
|
0.9555
|
57.92
|
Book Value Per Share
2 |
-0.1700
|
-0.2100
|
-0.1500
|
-0.0400
|
Cash Flow per Share
2 |
0
|
0
|
0.0200
|
0.0500
|
Capex
|
-
|
-
|
0.01
|
0.18
|
Capex / Sales
|
-
|
-
|
-
|
12.3%
|
Announcement Date
|
21-02-16
|
21-02-16
|
21-05-07
|
22-10-06
|
|
1st Jan change
|
Capi.
|
---|
| +16.67% | 50.81K | | +23.37% | 47.02B | | +48.83% | 41.86B | | -0.94% | 41.76B | | -5.86% | 28.8B | | +11.29% | 26.05B | | -20.92% | 19.15B | | +3.20% | 12.55B | | -2.67% | 11.82B | | +30.23% | 12.34B |
Other Biotechnology & Medical Research
|